Orchid Pharma Ltd - 524372 - Disbursement Of Amount Arising On Fractional Shares Pursuant To Reduction And Consolidation Of Share Capital As Per Approved Resolution Plan
Disbursement of amount arising on fractional shares pursuant to reduction and consolidation of share capital as per approved Resolution pla Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Earnings conference call (Q3FY2022) held on February 18, 2022 Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation regarding rescheduling of Investor Conference call on the financial performance of the Company for the quarter and nine months ended December 31, 2021 Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication- Unaudited financial results for the quarter and nine months ended December 31,2021 Orchid Pharma Ltd - 524372 - Intimation Regarding Postponement Of Investor Conference Call On The Financial Performance For The Quarter And Nine Months Ended December 31, 2021
Intimation regarding postponement of Investor Conference call on the financial performance for the quarter and nine months ended December 31, 2021 Orchid Pharma Ltd - 524372 - Unaudited Financial Results For The Quarter And Nine Months Ended December 31,2021
Unaudited financial results for the quarter and nine months ended December 31,2021 Orchid Pharma Ltd - 524372 - Board Meeting Outcome for Outcome Of Board Meeting Held On February 12,2022
Outcome of Board meeting held on February 12,2022 Orchid Pharma Ltd - 524372 - Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31, 2021.
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2022 ,inter alia, to consider and approve the Unaudited Financial results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2021 Orchid Pharma Ltd - 524372 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 25, 2022 for Dhanuka Laboratories Ltd Orchid Pharma Ltd - 524372 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0880 Name of the Signatory :- Nikita KDesignation :- Company Secretary and Compliance Officer